Project title: Epigenomic analysis of intestinal neuroendocrine cells and the epigenetic basis of NETs
Ramesh Shivdasani, MD, PhD Dana-Farber Cancer Institute
- Status: Completed
- Year(s): 2013
- Research Type: Basic
- Primary Tumor Site: Small intestine
- Area of Inquiry: Mapping NET dependencies
- Article/Video: Click Here
- Also seen in October 2016 eUpdate
Dr. Shivdasani’s laboratory studies how gastrointestinal stem cells make the decision to stop behaving like a stem cell and instead to differentiate into a neuroendocrine cell that might someday become a neuroendocrine tumor cell. Dr. Shivdasani will study how epigenetic regulation controls the process by which a stem cell becomes a neuroendocrine cell and to identify how changes in epigenetic regulation can promote development of neuroendocrine tumors. Epigenetic regulators determine which genes are turned on or off under specific conditions in a cell. While genes contain the instructions for assembling proteins, it is through epigenetic regulation that cells are able to control whether or not these proteins are actually produced.
Kim TH, Li F, Ferreiro-Neira I, Ho LL, Luyten A, Nalapareddy K, Long H, Verzi M, Shivdasani RA. Broadly permissive intestinal chromatin underlies lateral inhibition and cell plasticity. Nature. 2014 Feb 27;506(7489):511-5. doi: 10.1038/nature12903. Epub 2014 Jan 12.
- City: Boston
- State: Massachusetts
- Grant Duration: 4 years
- Awards: No information
- Sponsor: Pan-Mass Challenge
NETRF funds laboratory research to understand the development of neuroendocrine tumors and translational research to explore new concepts in treatment. Research grant descriptions and research updates from NETRF are not intended to serve as medical advice. It can take years for research discoveries to be fully validated and approved for patient care. Always consult your health care providers about your treatment options.